Daratumumab (Darzalex, Janssen Biotech) is a first-in-class monoclonal antibody directed against CD38 [13] and is approved by the U.S. Food and Drug Administration (FDA) for the treatment of newly diagnosed and relapsed/refractory multiple myeloma (MM). Here, CD38 is linked to Miyoshi myopathy.